The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias

Archives of Neurology

Volumn 59, Issue 10, 2002, Pages 1553-1562

  Mignot, Emmanuel ^a   Lammers, Gert Jan ^b   Ripley, Beth ^a   Okun, Michele ^a   Nevsimalova, Sonia ^c   Overeem, Sebastiaan ^b   Vankova, Jitka ^c   Black, Jed ^a   Harsh, John ^d   Bassetti, Claudio ^e   Schrader, Harald ^f   Nishino, Seiji ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c CHARLES UNIVERSITY   (Czech Republic)

^d UNIVERSITY OF SOUTHERN MISSISSIPPI   (United States)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^f TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

OREXIN;

ADULT; ARTICLE; CATAPLEXY; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; CIRCADIAN RHYTHM; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; FEMALE; HLA TYPING; HUMAN; HYPERSOMNIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NARCOLEPSY; NIEMANN PICK DISEASE; PARKINSON DISEASE; PRADER WILLI SYNDROME; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; SIGNAL DETECTION; SLEEP APNEA SYNDROME; SLEEP DISORDER;

ADULT; BIOLOGICAL MARKERS; CARRIER PROTEINS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HISTOCOMPATIBILITY TESTING; HLA-DQ ANTIGENS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NARCOLEPSY; NEUROPEPTIDES; NEUROTRANSMITTER AGENTS; POLYSOMNOGRAPHY; SENSITIVITY AND SPECIFICITY; SYMPATHOMIMETICS;

EID: 0036791834     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.59.10.1553     Document Type: Article

References (60)

1. Honda Y, Asaka A, Tanimura M, et al. A genetic study of narcolepsy and excessive daytime sleepiness in 308 families with narcolepsy or hypersomnia probands. In: Guilleminault C, Lugaresi E, eds. Sleep Wake Disorders Natural History, Epidemiology and Long Term Evolution. New York, NY: Raven Press; 1983: 187-199.
2. Overeem S, Mignot E, Gert van Dijk J, et al. Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives. J Clin Neurophysiol. 2001;18:78-105.
3. Okun ML, Lin L, Pelin Z, et al. Clinical aspects of narcolepsy-cataplexy across ethnic groups. Sleep. 2002;25:27-35.
4. Hublin C, Kaprio J, Partinen M, et al. The prevalence of narcolepsy: an epidemiological study of the Finnish Twin Cohort Ann Neurol. 1994;35:709-716.
5. Mignot E. Genetic and familial aspects of narcolepsy. Neurology. 1998;50(suppl1): S16 -S22.
6. Broughton WA, Broughton RJ. Psychosocial impact of narcolepsy. Sleep 1994; 17(8 suppl):S45-S49.
7. Nishino S, Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol. 1997;52:27-78.
8. Lammers G J, Arends J, Declerck AC, et al. Gammahydroxybutyrate and narcolepsy: a double-blind placebo-controlled study. Sleep. 1993;16:216-220.
9. American Academy of Sleep Medicine. international Classification of Sleep Disorders: Diagnostic and Coding Manual, Revised. Rochester, Minn: American Sleep Academy of Sleep Medicine; 2001.
10. Carskadon MA, Dement WC, Mitler MM, Roth T, Westbrook PR, Keenan S. Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness. Sleep. 1986;9: 519-524.
11. Aldrich MS, Chervin RD, Malow BA. Value of the multiple sleep latency test (MSLT) for the diagnosis of narcolepsy. Sleep. 1997;20; 620-629.
12. Moscovitch A, Partinen M, Guilleminault C. The positive diagnosis of narcolepsy and narcolepsy's borderland. Neurology. 1993;43:55-60.
13. Bassetti C, Aldrich MS. Idiopathic hypersomnia: a series of 42 patients. Brain. 1997;120:1423-1435.
14. Anic-LabatS, Guilleminault C, Kraemer HO, et al. Validation of a cataplexy questionnaire in 983 sleep-disorders patients. Sleep. 1999;22:77-87.
15. Ohayon MM, Priest RG, Caulet M, et al. Hypnagogic and hypnopompic hallucinations: pathological phenomena? Br J Psychiatry. 1996;169:459-467.
16. Ohayon MM, Zulley J, Guilleminault C, et al. Prevalence and pathologic associations of sleep paralysis in the general population. Neurology. 1999;52: 1194-1200.
17. Honda Y, Matuski K. Genetic aspects of narcolepsy. In: Thorpy MJ, ed. Handbook of Steep Disorders, New York, NY: Marcel Dekker Inc; 1990:217-234.
18. Aldrich MS. Diagnostic aspects of narcolepsy. Neurology. 1998; 50(suppl 1):82:S2-S7.
19. Juji T, Satake M, Honda Y, et al. HLA antigens in Japanese patients with narcolepsy: all the patients were DR2 positive. Tissue Antigens. 1984;24:316-319.
20. Mignot E, Lin X, Arrigoni J, et al. DQB1*0602 and DQA1*0102 (DQ1) are better markers than DR2 narcolepsy in Caucasian and black Americans. Sleep. 1994;17:S60-S66
21. Mignot E, Hayduk R, Black J, et al. HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep. 1997;20:1012-1020.
22. Mignot E, Lin L, Rogers W, et al. Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am J Hum Genet. 2001;68:686-699.
23. Lin L, Faraco J, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell. 1999;98:365-376.
24. Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell. 1999;98:437-451.
25. Nishino S, Ripley B, Overeem S, et al. Hypocretin (orexin) deficiency in human narcolepsy. Lancet. 2000; 355:39-40.
26. Nishino S, Ripley B, Overeem S, et al. Low cerebrospinal fluid hypocretin (orexin) and altered energy homeostasis in human narcolepsy. Ann Neurot 2001;50:381-388.
27. Ripley B, Overeem S, Fujiki N, et al. CSF hypocretin/orexin levels in narcolepsy and other neurogical conditions. Neurology. 2001;57:2253-2258.
28. Kanbayashi T, Inoue Y, Chiba S, et al. CSF hypocretin-1 (orexin-A) concentrations in narcolepsy with and without cataplexy and idiopathic hypersomnia. J Sleep Res. 2002; 11:91-93.
29. Peyron C, Faraco J, Rogers W, et al. A mutation in early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. NatMed. 2000;6: 991-997.
30. Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron. 2000;27:467-474.
31. De Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A. 1998;95:322-327.
32. Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998:92:573-585.
33. Peyron C, Tighe DK, van den Pol AN, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci. 1998;18:9996-10015.
34. Kilduff, TS, Peyron C. The hypocretin/orexin ligand -receptor system: implications for sleep and sleep disorders. Trends Neurosci. 2000;23:359-365
35. Hungs M, Mignot E, Hypocretin/orexin, sleep and narcolepsy. Bioessays. 2001; 23:397-408.
36. Mignot E. A commentary on the neurobiology of the hypocretin/orexin system. Neuropychopharmacology. 2001;25:S5- S13.
37. Willie JT, Chemelli RM, Sinton CM, et al. To eat or to sleep? orexin in the regulation of feeding and wakefulness. Ann Rev Neurosci. 2001;24:429-458.
38. Honda Y, Doi Y, Ninomiya R, et al. Increased frequency of non-insulin-dependent diabetes mellitus among narcoleptic patients. Sleep. 1986;9:254-259.
39. Schuld A, Hebebrand J, Geller F, et al. Increased body-mass index in patients with narcolepsy. Lancet. 2000;355:1274-1275.
40. Bassetti CL, Gugger M, Mathis J, et al. Cerebrospinal fluid levels of hypocretin (orexin) are normal in hypersomnolent patients without cataplexy [abstract]. Actas Fisiol, 2001;7:205.
41. Overeem S, Van Hilten JJ, Ripley B, et al. Normal hypocretin-1 levels in Parkinson's disease patients with excessive daytime sleepiness. Neurology. 2002;58:498-499.
42. Walters AS. Toward a better definition of the restless legs syndrome: the International Restless Legs Syndrome Study Group. Mov Disord. 1995; 10:634-642.
43. Kraemer HC. Evaluating medical tests: objective and quantitative guidelines. London, England: Sage Publication Inc; 1992.
44. Melberg A, Ripley B, Lin L, et al. Hypocretin deficiency in familial symptomatic narcolepsy. Ann Neurol. 2001;49:136-137.
45. Arii J, Kanbayashi T, Tanabe Y, et al. A hypersomnolent girl with decreased CSF hypocretin level after removal of a hypothalamic tumor. Neurology. 2001;56: 1775-1776.
46. Scammell TE, Nishino S, Mignot E, et al. Narcolepsy and low CSF orexin (hypocretin) concentration after a diencephalic stroke. Neurology. 2001; 56:1751-1753.
47. Challamel J MJ, Mazzola ME, Nevsimalova S, et al. Narcolepsy in children. Sleep. 1994; 17(suppl 8): S17-S20.
48. Cassidy SB. Prader-Willi syndrome. J Med Genet. 1997;34:917-923.
49. Manni R, Politini L, Nobili L, et al. Hypersomnia in the Prader-Willi syndrome: clinical-electrophysiological features and underlying factors. Clin Neurophysiol. 2001;112:800-805.
50. Katz ES, McGrath S, Marcus CL, Late-onset central hypoventilation with hypothalamic dysfunction: a distinct clinical syndrome. Pediatr Pulmonol. 2000;29: 62-68.
51. Hara J, Beuckmann CT, Nambu T, et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron. 2001;30:345-354
52. Smolik P, Roth B. Kleine-Levin syndrome ethiopathogenesis and treatment. Acta Univ Carol Med Monogr. 1988;128:5-94.
53. Mayer G, Leonhard E, Krieg J, et al. Endocrinological and polysomnographic findings in Kleine-Levin syndrome: no evidence for hypothalamic and circadian dysfunction. Sleep. 1998;21:278-284.
54. Yuan XQ, Wade CE. Neuroendocrine abnormalities in patients with traumatic brain injury. Front Neuroendocrtnol. 1991;12:209-230.
55. Guilleminault C, Mondini S. Mononucleosis and chronic daytime sleepiness: a long term follow-up study. Arch Intern Med. 1986;146:1333-1335.
56. Guilleminault C, Faull KF, Miles L, et al. Posttraumatic excessive daytime sleepiness: a review of 20 patients. Neurology. 1983;33:1584-1589.
57. Mignot E. A hundred years of narcolepsy ofnarcolepsy research., Arch ItalBioL 2001 ItalBiol.2001;139:207-220.
58. Adie WJ, Idiopathic narcolepsy: a disease sui generis; with remarks on the mechanisms of sleep. Brain. 1926;49:257-306.
59. Van Economo C. Sleep as a problem of localization. J Nerv Ment Dis. 1930;71: 249-259.
60. Lankford DA, Wellman JJ, O'Hara C. Posttraumatic narcolepsy in mild to moderate closed head injury. Sleep. 1994;17(suppl 8):S25-S28.